Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

topstockalerts Jul. 6 at 10:19 PM

$PYPD every consolidation seems to strengthen the case.

0 · Reply

Finnish_boy Jul. 6 at 8:50 PM

$PYPD Break out? 500k volume. Highest since June 2025 when blockbuster ph3 results were out. Stock should have been $10 already a year ago. And SP still $5. What a bargain.

0 · Reply

Finnish_boy Jul. 6 at 8:23 PM

$PYPD $10 very soon. Watch it.

1 · Reply

Finnish_boy Jul. 6 at 4:02 PM

$PYPD TICK TOCK.. series of catalysts starts next week. We will start with the most major one: US DEAL.. lock in!

1 · Reply

Finnish_boy Jul. 6 at 3:00 PM

$PYPD Fill the gap

0 · Reply

Finnish_boy Jul. 6 at 2:57 PM

$PYPD US deal soon !!!!!!! YES ! NDA approval in 2 weeks also -> re-rating.

0 · Reply

PaulNipkow Jul. 6 at 8:32 AM

$PYPD The GLP-1 data can be an eye-opener !

1 · Reply

Finnish_boy Jul. 5 at 1:23 PM

$PYPD I expect NDA approval 20th-24th. At the latest 27-30th July.

0 · Reply

Finnish_boy Jul. 5 at 8:53 AM

$PYPD NDA approval (priority review/PDUFA date announcement) is not requirement for signing/announcing US deal imho. I think it's still more lilely that they announce the deal in July before NDA approval. But my best single guess is a week before Q2 report in August. Does someone know more about this?

0 · Reply

Finnish_boy Jul. 4 at 3:34 PM

$PYPD Doesnt mean anything but in 2022 they announced EU partnership deal at start of August on Wednesday a week before Q2 report also.

0 · Reply

PolyPid completes NDA submission to FDA for D-PLEX100

Jun 1, 2026, 8:30 AM EDT - 5 weeks ago

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

May 28, 2026, 11:30 AM EDT - 5 weeks ago

PolyPid Transcript: Lytham Partners Spring 2026 Investor Conference

May 20, 2026, 8:30 AM EDT - 6 weeks ago

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

2026-05-13T17:09:41.000Z - 7 weeks ago

PolyPid reports Q1 EPS (35c), consensus (43c)

May 13, 2026, 8:30 AM EDT - 7 weeks ago

PolyPid Earnings Call Transcript: Q1 2026

May 13, 2026, 8:30 AM EDT - 7 weeks ago

PolyPid Earnings release: Q1 2026

May 13, 2026, 7:30 AM EDT - 7 weeks ago

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026, 8:00 AM EDT - 2 months ago

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

Apr 28, 2026, 8:30 AM EDT - 2 months ago

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 13, 2026, 9:15 AM EDT - 3 months ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Mar 31, 2026, 8:30 AM EDT - 3 months ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

2026-03-17T12:46:11.000Z - 3 months ago

PolyPid granted $4.3M waiver from FDA for D-Plex application

Mar 17, 2026, 8:30 AM EDT - 3 months ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 10, 2026, 1:40 PM EDT - 4 months ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Feb 25, 2026, 8:35 AM EST - 4 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Annual report: Q4 2025

Feb 11, 2026, 8:30 AM EST - 5 months ago

PolyPid Earnings release: Q4 2025

Feb 11, 2026, 7:30 AM EST - 5 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 11, 2026, 6:00 AM EST - 5 months ago

PolyPid Slides: Investor presentation

Jan 28, 2026, 8:00 AM EST - 5 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 15, 2026, 10:30 AM EST - 6 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

2025-12-16T13:41:48.000Z - 7 months ago

PolyPid appoints Story as Chairman of Board of Directors

Dec 16, 2025, 8:30 AM EST - 7 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 10, 2025, 11:30 AM EST - 7 months ago

PolyPid Transcript: KOL Event

2025-12-03T13:35:51.000Z - 7 months ago

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

Dec 3, 2025, 8:30 AM EST - 7 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 7 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 18, 2025, 7:00 AM EST - 8 months ago

PolyPid Slides: Corporate Presentation

2025-11-13T11:16:03.000Z - 8 months ago

PolyPid price target lowered to $9 from $10 at Roth Capital

Nov 12, 2025, 8:30 AM EST - 8 months ago

PolyPid Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 8 months ago

PolyPid Earnings release: Q3 2025

2025-11-12T12:41:32.000Z - 8 months ago

PolyPid sees cash runway ‘well into’ 2026

2025-11-12T12:35:15.000Z - 8 months ago

PolyPid reports Q3 EPS (37c), consensus (52c)

Nov 12, 2025, 7:30 AM EST - 8 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 8 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 8 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 12:30 PM EDT - 9 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 8:45 AM EDT - 9 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 10 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

2025-09-16T12:45:43.000Z - 10 months ago

PolyPid completes Israeli Ministry of Health GMP inspection

Sep 16, 2025, 8:30 AM EDT - 10 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 10 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

2025-08-14T13:30:37.000Z - 11 months ago

PolyPid price target lowered to $13 from $15 at Craig-Hallum

2025-08-14T12:05:26.000Z - 11 months ago

PolyPid price target raised to $10 from $9 at Roth Capital

Aug 13, 2025, 8:30 AM EDT - 11 months ago

PolyPid Earnings Call Transcript: Q2 2025

Aug 13, 2025, 8:30 AM EDT - 11 months ago

PolyPid Earnings release: Q2 2025

2025-08-13T11:35:50.000Z - 11 months ago

PolyPid reports Q2 EPS (78c), consensus (55c)

2025-08-13T11:35:37.000Z - 11 months ago

PolyPid sees cash runway ‘well into’ 2026

Aug 13, 2025, 7:30 AM EDT - 11 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

2025-08-12T12:20:23.000Z - 11 months ago

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 11 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

2025-07-29T20:12:22.000Z - 1 year ago

PolyPid files to sell 7.63M ordinary shares for holders

Jul 29, 2025, 8:00 AM EDT - 1 year ago

PolyPid Registration statement: Registration Filing

Jul 15, 2025, 8:00 AM EDT - 1 year ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

2025-06-18T12:06:16.000Z - 1 year ago

PolyPid price target lowered to $9 from $12 at Roth Capital

2025-06-17T15:05:27.000Z - 1 year ago

PolyPid price target lowered to $9 from $12 at Roth Capital

Jun 16, 2025, 7:20 PM EDT - 1 year ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 12, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Corporate Presentation

Jun 11, 2025, 9:42 AM EDT - 1 year ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 1 year ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 1 year ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Transcript: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Press release: Status Update

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Slides: Status Update

Jun 9, 2025, 7:30 AM EDT - 1 year ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:00 AM EDT - 1 year ago

PolyPid Slides: Investor Presentation

Jun 6, 2025, 4:05 PM EDT - 1 year ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Annual report: Q4 2024

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q4 2024

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 21, 2025, 7:00 AM EST - 1 year ago

PolyPid Registration statement: Registration Filing

Jan 14, 2025, 6:00 PM EST - 1 year ago

PolyPid Slides: Corporate Presentation

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 14, 2024, 8:30 AM EST - 1 year ago

PolyPid Transcript: 2024 Sidoti Virtual Micro-Cap Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings release: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

topstockalerts Jul. 6 at 10:19 PM

$PYPD every consolidation seems to strengthen the case.

0 · Reply

Finnish_boy Jul. 6 at 8:50 PM

$PYPD Break out? 500k volume. Highest since June 2025 when blockbuster ph3 results were out. Stock should have been $10 already a year ago. And SP still $5. What a bargain.

0 · Reply

Finnish_boy Jul. 6 at 8:23 PM

$PYPD $10 very soon. Watch it.

1 · Reply

Finnish_boy Jul. 6 at 4:02 PM

$PYPD TICK TOCK.. series of catalysts starts next week. We will start with the most major one: US DEAL.. lock in!

1 · Reply

Finnish_boy Jul. 6 at 3:00 PM

$PYPD Fill the gap

0 · Reply

Finnish_boy Jul. 6 at 2:57 PM

$PYPD US deal soon !!!!!!! YES ! NDA approval in 2 weeks also -> re-rating.

0 · Reply

PaulNipkow Jul. 6 at 8:32 AM

$PYPD The GLP-1 data can be an eye-opener !

1 · Reply

Finnish_boy Jul. 5 at 1:23 PM

$PYPD I expect NDA approval 20th-24th. At the latest 27-30th July.

0 · Reply

Finnish_boy Jul. 5 at 8:53 AM

0 · Reply

Finnish_boy Jul. 4 at 3:34 PM

$PYPD Doesnt mean anything but in 2022 they announced EU partnership deal at start of August on Wednesday a week before Q2 report also.

0 · Reply

Finnish_boy Jul. 4 at 3:25 PM

$PYPD My best guess. But you never know.

1 · Reply

CARTE_BLANCHE_DEVEREAUX Jul. 3 at 6:55 PM

$SLS $ATHE $CING $PYPD It's been 1 year (and 2 days) since I posted this. How did you guys do this year? What do you guys have planned for the next year? Are you paying attention (and contributing) to the Discord?

2 · Reply

PaulNipkow Jul. 3 at 8:55 AM

$PYPD Nap time over soon ?

1 · Reply

PaulNipkow Jul. 2 at 8:25 AM

$PYPD

0 · Reply

Finnish_boy Jul. 2 at 6:47 AM

$PYPD Would be super helpful to know when the deal will be out. Is it late August after NDA approval or is it mid-July. I dont know.

0 · Reply

Finnish_boy Jun. 30 at 8:14 AM

$PYPD Management has very high ambitions. They go alone but the first programs will be partnered being more cost-friendly. They are already planning where they build a second factory.

1 · Reply

Finnish_boy Jun. 30 at 7:47 AM

$PYPD Future giant pharma? Scalable platform technology with super robust PH3 data. Market cap under 100M. "As a delivery platform, it can be applied to multiple classes of therapeutics that struggle with stability, toxicity, or dosing frequency under traditional systemic administration." https://pulse2.com/polypid-profile-ori-warshavsky-interview/

0 · Reply

Finnish_boy Jun. 29 at 9:20 PM

$PYPD Look at volume. Big green days high volume. Big boys try to load as much as they can under $5. Pretty transparent.😂if retail investors were active on this stock, stock would be already $10

1 · Reply

Finnish_boy Jun. 29 at 4:00 PM

$PYPD TICK TOCK. Bigger players dont want to SP shoot up !! warrants sellers are their friends, they can short sell some to control SP, shorties were up 200%. It's all about couple of weeks waiting anymore. I have totally full position. SP going to $10 by August. Next year $20.

0 · Reply

PaulNipkow Jun. 29 at 10:42 AM

$PYPD the best example that ppl are like sheep (… no, not the smart ones from the movie *Sheep Detectives*) ! They all follow one another, and for the most part, they’re blind to what’s right in front of them and deaf to what’s being said. 780m by Lilly vs 1/10 here for a phase 3

0 · Reply

Finnish_boy Jun. 28 at 6:45 PM

$PYPD CEO refers Camurus x Eli Lilly deal.. up to 870M !! PolyPid market cap under 100M !! Potential multibagger already within a year. I think they sign partnerhship also with GPL-1 program already next year !!🤑

2 · Reply

Finnish_boy Jun. 28 at 11:00 AM

$HROW $PYPD Buy both as much as you can under $50 and $5 levels. Both will more than double within a year.

0 · Reply

Market Cap	95.80M
Revenue (ttm)	0.00
Net Income (ttm)	-34.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	504,100
Avg Vol	131,568
Day's Range	N/A - N/A
Shares Out	19.08M
Stochastic %K	69%
Beta	1.40
Analysts	Strong Sell
Price Target	$12.25